{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:03:52Z","timestamp":1793037832315,"version":"4.5.0"},"reference-count":180,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaad.2023.02.073","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T21:06:02Z","timestamp":1690491962000},"page":"911-926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management"],"prefix":"10.1016","volume":"90","author":[{"given":"Brian M.","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanade","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Kwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Bolognia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.02.073_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2023.02.073_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.073_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: key regulators of T-cell-mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"key":"10.1016\/j.jaad.2023.02.073_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00128071-200102030-00004","article-title":"Drug-induced urticaria. Recognition and treatment","volume":"2","author":"Shipley","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib8","series-title":"Dermatology","first-page":"304","article-title":"Urticaria and angioedema","author":"Grattan","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/jdv.13832","article-title":"Comparative histological analysis of drug-induced maculopapular exanthema and DRESS","volume":"30","author":"Skowron","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib10","series-title":"Dermatology","first-page":"348","article-title":"Drug reactions","author":"Valeyrie-Allanore","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib11","first-page":"612","volume":"130","author":"Saissi","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6928363","article-title":"Immunohistopathological findings of severe cutaneous adverse drug reactions","volume":"2017","author":"Orime","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaad.2023.02.073_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","article-title":"Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US","volume":"158","author":"Creadore","year":"2022","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.jaad.2023.02.073_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.12783","article-title":"Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"170","author":"Chi","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/jdv.13212","article-title":"Drug reaction with\u00a0eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases","volume":"29","author":"Skowron","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib21","series-title":"Dermatology","first-page":"332","article-title":"Erythema multiforme, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis","author":"H\u00f6tzenecker","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib23","first-page":"322","article-title":"DRESS syndrome: clinical myths and pearls","volume":"102","author":"Isaacs","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2023.02.073_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13671-021-00348-z","article-title":"Updates and insights in the diagnosis and management of DRESS syndrome","volume":"10","author":"Schunkert","year":"2021","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2217\/pgs-2020-0014","article-title":"Gene expression profiling in allopurinol-induced severe cutaneous adverse\u00a0reactions in Vietnamese","volume":"21","author":"van Nguyen","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2023.02.073_bib26","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/acs.chemrestox.1c00047","article-title":"Extracellular vesicles from human plasma Show a distinctive proteome and miRNome profile in patients with severe cutaneous adverse reactions","volume":"34","author":"Salinas-Jaramillo","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jaad.2023.02.073_bib27","series-title":"Dermatology","first-page":"1400","article-title":"Human herpesviruses","author":"Downing","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib28","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00431-021-04010-5","article-title":"Viral rashes mimicking drug reaction with eosinophilia and systemic symptoms syndrome in children after \u03b2-lactams intake: a diagnostic challenge","volume":"180","author":"Dondi","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaad.2023.02.073_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1060028016669525","article-title":"Antibiotic-induced rash in patients with infectious mononucleosis","volume":"51","author":"Thompson","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2023.02.073_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2018.06.022","article-title":"Sensitization to amoxicillin\/clavulanic acid may underlie severe rashes in children treated for infectious mononucleosis","volume":"7","author":"Mori","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib31","series-title":"Dermatology","first-page":"1425","article-title":"Other viral diseases","author":"Mancini","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","article-title":"The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11908-010-0119-y","article-title":"Staphylococcal toxic shock syndrome: mechanisms and management","volume":"12","author":"Silversides","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib34","article-title":"Toxic shock syndrome","volume":"2015","author":"Inokuchi","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s15010-018-1238-x","article-title":"Chronic meningococcemia: a report of 26 cases and literature review","volume":"47","author":"Lefevre","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.jaad.2023.02.073_bib36","series-title":"Dermatology","first-page":"1319","article-title":"Rickettsial diseases","author":"Walker","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib37","series-title":"Dermatology","first-page":"1447","article-title":"Sexually transmitted infections","author":"Stary","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12016-017-8667-7","article-title":"Current perspectives on erythema multiforme","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib39","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15792","article-title":"Erythema multiforme-like drug eruption associated with dupilumab treatment: report of an unusual case","volume":"35","author":"Long","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.02.073_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2023.02.073_bib42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2133.2007.07784.x","article-title":"Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome","volume":"156","author":"Kano","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2230.2008.02823.x","article-title":"Drug rash with eosinophilia and systemic symptoms and graft-versus-host disease developing sequentially in a patient","volume":"34","author":"Natkunarajah","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib45","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/bmt.2010.324","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant","volume":"46","author":"Lopez-Anglada","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2023.02.073_bib46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ced.12246","article-title":"Increased ratio of FoxP3+ regulatory T cells\/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms","volume":"39","author":"Morito","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaad.2010.07.042","article-title":"Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions","volume":"65","author":"Byun","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib49","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/1346-8138.14233","article-title":"Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea","volume":"45","author":"Oh","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-248229","article-title":"Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis","volume":"15","author":"Zgheib","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib51","article-title":"Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome","volume":"2018","author":"Morita","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib52","series-title":"Dermatology","first-page":"2148","article-title":"Other lymphoproliferative and myeloproliferative diseases","author":"Massone","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib53","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2023.02.073_bib54","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.12788\/cutis.0498","article-title":"Angioimmunoblastic T-cell lymphoma mimicking DRESS syndrome","volume":"109","author":"Keefe","year":"2022","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2023.02.073_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000458752","article-title":"Angioimmunoblastic T-cell lymphoma mimicking drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)","volume":"9","author":"Mangana","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib57","series-title":"Dermatology","first-page":"440","article-title":"Eosinophil-associated dermatoses","author":"Leiferman","year":"2018"},{"key":"10.1016\/j.jaad.2023.02.073_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4168\/aair.2014.6.3.216","article-title":"Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome","volume":"6","author":"Kim","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaad.2023.02.073_bib59","article-title":"A multi-center, retrospective analysis of the diagnosis, management, and outcomes among patients withdrug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","author":"Emge","year":"2022","journal-title":"Medical Dermatology Society"},{"key":"10.1016\/j.jaad.2023.02.073_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/idoj.idoj_196_21","article-title":"RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): a comparative analysis","volume":"13","author":"Sasidharanpillai","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaad.2023.02.073_bib61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-7-72","article-title":"Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?","volume":"7","author":"Bouvresse","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.jaad.2023.02.073_bib62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/ijd.15196","article-title":"Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review","volume":"60","author":"Yang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"Ogawa","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.073_bib64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.alit.2015.06.007","article-title":"Usefulness of rapid measurement of serum thymus and activation-regulated chemokine level in diagnosing drug-induced hypersensitivity syndrome","volume":"64","author":"Komatsu-Fujii","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.073_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1684\/ejd.2014.2477","volume":"25","author":"Miyagawa","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.alit.2016.06.003","article-title":"Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions","volume":"66","author":"Komatsu-Fujii","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.073_bib67","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/1346-8138.15211","article-title":"Drug-induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease","volume":"47","author":"Satake","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/jir.2019.0012","article-title":"Cytokines\/chemokines: novel biomarkers associated with severe cutaneous adverse reactions","volume":"40","author":"Zhang","year":"2020","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jaad.2023.02.073_bib69","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2021.03.075","article-title":"Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: a prospective case-control study","volume":"85","author":"Choudhary","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib70","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/biom11060847","article-title":"Chemokines in severe cutaneous adverse reactions (SCARs)","volume":"11","author":"Miyagawa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaad.2023.02.073_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2020.03.010","article-title":"Association of interleukin-6 and tumor necrosis factor-\u03b1 with mortality in hospitalized patients with cancer","volume":"84","author":"Stoll","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib72","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2133.2012.10921.x","article-title":"Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome","volume":"167","author":"Saito","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib73","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bjd.13162","article-title":"The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"171","author":"Fujita","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib74","doi-asserted-by":"crossref","first-page":"E2277","DOI":"10.1210\/jc.2012-2054","article-title":"High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome","volume":"97","author":"Onuma","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2023.02.073_bib75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.12948","article-title":"Elevated serum thymus and activation-regulated chemokine (TARC\/CCL17) relates to reactivation of human herpesvirus 6 in drug\u00a0reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DIHS)","volume":"171","author":"Ogawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2014.01.007","article-title":"TNF-alpha as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"74","author":"Uno","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.073_bib77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2016.05.001","article-title":"Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"83","author":"Miyagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2023.02.073_bib79","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/ijd.13350","article-title":"Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression","volume":"55","author":"Weinborn","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib80","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.alit.2017.06.001","article-title":"The thymus and\u00a0activation-regulated chemokine (TARC) level in serum at\u00a0an early stage of a drug eruption is a prognostic biomarker\u00a0of\u00a0severity of systemic inflammation","volume":"67","author":"Komatsu-Fujii","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2023.02.073_bib81","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bjd.16132","article-title":"Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome","volume":"178","author":"Nakamura-Nishimura","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1684\/ejd.2017.3211","article-title":"Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"28","author":"Yang","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib83","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","article-title":"Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome","volume":"139","author":"Tsai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib84","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for\u00a0assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib85","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaad.2018.10.039","article-title":"Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions","volume":"80","author":"Mori","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib86","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/1346-8138.15548","article-title":"Parallel changes in serum thymus and activation-regulated chemokine levels in response to flare-ups in drug-induced hypersensitivity syndrome","volume":"47","author":"Kanatani","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib87","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3465","article-title":"Correlation between expression of CD134, a human herpesvirus 6 cellular receptor, on CD4+ T cells and Th2-type immune responses in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"100","author":"Miyagawa","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijid.2020.08.078","volume":"100","author":"Mizukawa","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaad.2023.02.073_bib89","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bjd.18942","article-title":"The interferon-\u03b3-induced protein 10\/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms","volume":"183","author":"Yang","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib90","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1111\/1346-8138.16341","article-title":"Sequential screening of biomarkers in a case of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms occurring with virus reactivation and autoimmune disease","volume":"49","author":"Lee","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib91","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jid.2021.11.008","article-title":"Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification","volume":"142","author":"Mizukawa","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib92","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jamadermatol.2022.3491","article-title":"Predicting DRESS syndrome recurrence\u2014the ReDRESS score","volume":"158","author":"Sharma","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib93","series-title":"A Multi-Center, Retrospective Analysis of the Diagnosis, Management, and Outcomes Among Patients With Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)","author":"Emge","year":"2022"},{"key":"10.1016\/j.jaad.2023.02.073_bib94","first-page":"e162","article-title":"Drug reaction with eosinophilia and systemic symptoms in children: a prospective study","volume":"33","author":"Sasidharanpillai","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib95","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaip.2016.04.026","article-title":"A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions","volume":"4","author":"Trubiano","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib96","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pds.4774","article-title":"Variation of clinical manifestations according to culprit drugs in DRESS syndrome","volume":"28","author":"Sim","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2023.02.073_bib97","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jaad.2020.03.019","article-title":"Drug reaction with eosinophilia and systemic symptoms within 1 week of exposure to the drug","volume":"83","author":"Sasidharanpillai","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib98","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","article-title":"Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study","volume":"82","author":"Soria","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib99","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/jdv.17631","article-title":"Specific features of amoxicillin-associated drug reaction with eosinophilia and systemic symptoms syndrome: a nationwide study","volume":"35","author":"Largeau","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaip.2021.07.025","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): series of 49 French pediatric cases","volume":"10","author":"Bedouelle","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib101","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2340\/00015555-1222","article-title":"Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms","volume":"92","author":"Wongkitisophon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib102","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.jaip.2021.02.060","article-title":"DRESS and AGEP reactions to iodinated contrast media: a French case series","volume":"9","author":"Soria","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib103","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s00520-021-06543-9","article-title":"Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review","volume":"30","author":"Maloney","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2023.02.073_bib104","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4103\/0366-6999.204104","article-title":"Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade","volume":"130","author":"Wang","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaad.2023.02.073_bib105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/dtb.2021.235803rep","article-title":"Republished: case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure","volume":"59","author":"Winward","year":"2021","journal-title":"Drug Ther Bull"},{"key":"10.1016\/j.jaad.2023.02.073_bib106","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5415\/apallergy.2014.4.3.156","article-title":"A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy","volume":"4","author":"Thong","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaad.2023.02.073_bib107","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2018.12.017","article-title":"Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications","volume":"147","author":"Ban","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaad.2023.02.073_bib108","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib109","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib110","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib111","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2020.03.095","article-title":"Viral reactivation in hospitalized patients with drug reaction with eosinophilia and systemic symptoms: a retrospective study from a tertiary medical center in the United States","volume":"83","author":"Milani-Nejad","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib112","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamadermatol.2013.2018","article-title":"Saliva polymerase chain reaction assay for detection and follow-up of herpesvirus reactivation in patients with drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"149","author":"Descamps","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib113","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.annder.2021.02.002","article-title":"Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): a monocenter retrospective study of 20 cases","volume":"148","author":"Brin","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib114","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1684\/ejd.2011.1300","article-title":"Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone","volume":"21","author":"Natkunarajah","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1346-8138.16230","article-title":"Is steroid pulse therapy a suitable treatment for drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms? A systematic review of case reports in patients treated with corticosteroids in Japan","volume":"49","author":"Hashizume","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib116","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1468-3083.2012.04547.x","article-title":"Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids","volume":"27","author":"Uhara","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib117","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib118","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","article-title":"Characteristics of liver injury in drug-induced systemic hypersensitivity reactions","volume":"69","author":"Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib119","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/TP.0000000000001655","article-title":"Acute liver failure\/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors","volume":"101","author":"Ichai","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2023.02.073_bib120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib121","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/1346-8138.15294","article-title":"Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"47","author":"Tohyama","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib122","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib123","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00007890-198608000-00010","article-title":"Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study","volume":"42","author":"Novick","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2023.02.073_bib124","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jid.2018.03.1496","article-title":"Selective use of cyclosporine for Stevens-Johnson syndrome\/toxic epidermal necrolysis may exclude patients with poor prognostic factors","volume":"138","author":"Noe","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.148.4.dlt120002-c","article-title":"Poor benefit\/risk balance of intravenous immunoglobulins in DRESS","volume":"148","author":"Joly","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2004.12.013","article-title":"Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome","volume":"209","author":"Kano","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2023.02.073_bib127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaip.2013.11.008","article-title":"Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms","volume":"2","author":"Galv\u00e3o","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib128","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaip.2017.10.016","article-title":"Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome","volume":"6","author":"Marcus","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib129","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/imj.14997","article-title":"Drug rash with eosinophilia and systemic symptoms syndrome without eosinophilia managed with intravenous immunoglobulin","volume":"50","author":"Kerkemeyer","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaad.2023.02.073_bib130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/cts.13201","article-title":"Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome","volume":"15","author":"Sim","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaad.2023.02.073_bib131","first-page":"1","article-title":"Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"23","author":"Gschwend","year":"2022","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaad.2023.02.073_bib132","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jdcr.2019.07.004","article-title":"Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib","volume":"5","author":"Damsky","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib133","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jaccas.2020.02.004","article-title":"A novel treatment for a rare cause of cardiogenic shock","volume":"2","author":"Chowdhury","year":"2020","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib134","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2023.02.073_bib135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7326\/0003-4819-150-3-200902030-00027","article-title":"Hypersensitivity myocarditis associated with azithromycin exposure","volume":"150","author":"Pursnani","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2023.02.073_bib136","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1053\/j.ajkd.2009.10.054","article-title":"Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation","volume":"55","author":"Laban","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaad.2023.02.073_bib137","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2016.2220","article-title":"Cyclosporine treatment of drug-induced hypersensitivity syndrome","volume":"152","author":"Kirchhof","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib138","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4103\/ijdvl.IJDVL_1084_16","article-title":"Treatment of drug-induced hypersensitivity syndrome with cyclosporine","volume":"83","author":"Zhang","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2023.02.073_bib139","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/1346-8138.14207","article-title":"Short course of cyclosporin A as a treatment option for drug-induced hypersensitivity syndrome: case reports and review of the published work","volume":"45","author":"Hashizume","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib140","first-page":"41","article-title":"Cyclosporine treatment of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and brief review of the literature","volume":"2018","author":"Kuschel","year":"2018","journal-title":"Pract Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib141","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaip.2019.06.020","article-title":"Severe acute hepatitis in drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome resolved following cyclosporine","volume":"8","author":"Ton","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib142","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.anai.2021.08.012","article-title":"Successful treatment of corticosteroid-dependent drug reaction with eosinophilia and systemic symptoms with cyclosporine","volume":"127","author":"Su","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib143","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jdcr.2017.05.006","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-\u03b1 inhibitor","volume":"3","author":"Leman","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000388","article-title":"Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with\u00a0Eosinophilia and Systemic Symptoms (DRESS) syndrome\u00a0after tocilizumab and infliximab administration","volume":"8","author":"Maximova","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2023.02.073_bib145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2340\/00015555-1168","article-title":"High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome","volume":"92","author":"Kito","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2023.02.073_bib146","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jaad.2020.03.081","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib147","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pde.14044","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature","volume":"37","author":"Metterle","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib148","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/pde.14446","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature, with a focus on relapsing cases","volume":"38","author":"Afiouni","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib149","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome\u00a0successfully treated with mepolizumab","volume":"6","author":"Ange","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib150","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231355","article-title":"Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS","volume":"12","author":"Thein","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib151","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242240","article-title":"Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis","volume":"14","author":"Truong","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2023.02.073_bib152","first-page":"1353","article-title":"[Drug rash with eosinophilia and\u00a0systemic symptoms (DRESS) attributed to the oral skin-care supplement Imedeen]","volume":"149","author":"van Leeuwen","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.jaad.2023.02.073_bib153","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","article-title":"Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with\u00a0persistent myocarditis","volume":"62","author":"Shaughnessy","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib154","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2010.12.013","article-title":"Fulminant myocarditis as a late sequela of DRESS: two cases","volume":"65","author":"Bourgeois","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib155","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib156","doi-asserted-by":"crossref","first-page":"Cs57","DOI":"10.12659\/MSM.883198","article-title":"Treatment of DIHS\/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis","volume":"18","author":"Moling","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jaad.2023.02.073_bib157","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/s10165-004-0316-3","article-title":"An infant with \u03b3-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second \u03b3-globulin treatment","volume":"14","author":"Miyamae","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib158","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1744-9987.2005.00320.x","article-title":"A case of drug-induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange","volume":"9","author":"Higuchi","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jaad.2023.02.073_bib159","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2012-2117","article-title":"Severe DRESS syndrome managed with therapeutic plasma exchange","volume":"131","author":"Alexander","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2023.02.073_bib160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib161","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2023.02.073_bib162","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you\u00a0Safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib163","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cod.14063","article-title":"Skin tests in the work-up of cutaneous adverse drug reactions: a review and update","volume":"86","author":"Barbaud","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2023.02.073_bib164","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u22175701 screening for\u00a0hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.02.073_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B\u221757:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(\u00ae) observational database: a cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jaad.2023.02.073_bib166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib167","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cpt.2008","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin\u00a0dosing: 2020 update","volume":"109","author":"Karnes","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaad.2023.02.073_bib168","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib169","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cod.14090","article-title":"Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): a literature review","volume":"86","author":"de Groot","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2023.02.073_bib170","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12016-022-08924-2","article-title":"The role of patch testing in evaluating delayed hypersensitivity reactions to medications","volume":"62","author":"Woodruff","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib171","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib172","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bjd.17835","article-title":"Are drug intradermal tests dangerous to explore cross-reactivity and co-sensitization in DRESS?","volume":"181","author":"Soria","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib173","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamadermatol.2013.6698","article-title":"Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features","volume":"150","author":"Tetart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib174","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib175","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-\u0393 ELISpot in severe cutaneous adverse reactions to first-line anti-tuberculosis drugs in an HIV endemic Setting","volume":"142","author":"Porter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.02.073_bib176","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaip.2013.05.007","article-title":"Cytokine gene expression profiling to help identify a safe antibiotic in a patient with drug rash with eosinophilia and systemic symptoms","volume":"1","author":"Bhardwaj","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib177","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2016.03.023","article-title":"Peripheral blood mononuclear cell gene expression testing and the heterogeneity of T-cell-mediated drug reaction with eosinophilia and systemic symptoms syndrome","volume":"116","author":"Schmitz","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2023.02.073_bib178","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/toxsci\/kfac062","article-title":"Potential biomarker identification by RNA-seq analysis in antibiotic-related drug reaction with eosinophilia and systemic symptoms (DRESS): a pilot study","volume":"189","author":"Teo","year":"2022","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jaad.2023.02.073_bib179","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jaip.2019.10.005","article-title":"Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions","volume":"8","author":"Trubiano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2023.02.073_bib180","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in\u00a0vivo and ex\u00a0vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223024039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:01:07Z","timestamp":1717606867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223024039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":180,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0190962223024039"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.073","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.072","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(24)00154-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}